Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cancer Advances, Inc.
Durham, North Carolina, USAcanceradvances.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
PAS has been studied in multiple clinical trials with over 1,500 human subjects, demonstrating excellent safety and tolerability. Clinical trials have shown PAS can increase survival times by 50% in GI clinical trials by inducing antibodies to Gastrin. Recent research shows PAS can alter the tumor microenvironment, potentially enhancing the efficacy of PD-1 Checkpoint Inhibitors by turning "cold" tumors "hot"[1][2][8].
- Therapeutic areas
- Oncology
- Modalities
- VaccinesImmunomodulators
- Industry
- Biotech
Beyond the preview
Go deeper on Cancer Advances, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cancer Advances, Inc..